{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:53:04Z","timestamp":1790639584065,"version":"4.1.0"},"reference-count":61,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Context: Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) is debated as benefits are inconstant. Molecular signatures for DCIS have been developed to stratify the risk of local recurrence (LR) and therefore guide the decision of RT. Objective: To evaluate, in women with DCIS treated by BCS, the impact of adjuvant RT on LR according to the molecular signature risk stratification. Methodology: We conducted a systematic review and meta-analysis of five articles including women with DCIS treated by BCS and with a molecular assay performed to stratify the risk, comparing the effect of BCS and RT versus BCS alone on LR including ipsilateral invasive (InvBE) and total breast events (TotBE). Results: The meta-analysis included 3478 women and evaluated two molecular signatures: Oncotype Dx DCIS (prognostic of LR), and DCISionRT (prognostic of LR and predictive of RT benefit). For DCISionRT, in the high-risk group, the pooled hazard ratio of BCS + RT versus BCS was 0.39 (95%CI 0.20\u20130.77) for InvBE and 0.34 (95%CI 0.22\u20130.52) for TotBE. In the low-risk group, the pooled hazard ratio of BCS + RT versus BCS was significant for TotBE at 0.62 (95%CI 0.39\u20130.99); however, it was not significant for InvBE (HR = 0.58 (95%CI 0.25\u20131.32)), Discussion: Molecular signatures are able to discriminate high- and low-risk women, high-risk ones having a significant benefit of RT in the reduction of invasive and in situ local recurrences, while in low-risk ones RT did not have a benefit for preventing invasive breast recurrence. The risk prediction of molecular signatures is independent of other risk stratification tools developed in DCIS, and have a tendency toward RT de-escalation. Further studies are needed to assess the impact on mortality.<\/jats:p>","DOI":"10.3390\/jcm12052036","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T02:06:43Z","timestamp":1678068403000},"page":"2036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Molecular Signatures in Ductal Carcinoma In Situ (DCIS): A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"12","author":[{"given":"Drissa","family":"Ouattara","sequence":"first","affiliation":[{"name":"Surgery Department, Point G University Hospitals, Bamako P.O. Box 251, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0210","authenticated-orcid":false,"given":"Carole","family":"Mathelin","sequence":"additional","affiliation":[{"name":"Strasbourg University Hospital, 1 Avenue Moli\u00e8re, 67200 Strasbourg, France"},{"name":"Surgical Oncology Department, ICANS Institute of Oncology Strasbourg Europe, 17 Avenue Albert Calmette, CEDEX, 67200 Strasbourg, France"},{"name":"IGBMC Institute of Genetics, Molecular and Cellular Biology, CNRS, UMR7104 INSERM U964, Strasbourg University, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-6195","authenticated-orcid":false,"given":"Tolga","family":"\u00d6zmen","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-6378","authenticated-orcid":false,"given":"Massimo","family":"Lodi","sequence":"additional","affiliation":[{"name":"Strasbourg University Hospital, 1 Avenue Moli\u00e8re, 67200 Strasbourg, France"},{"name":"Surgical Oncology Department, ICANS Institute of Oncology Strasbourg Europe, 17 Avenue Albert Calmette, CEDEX, 67200 Strasbourg, France"},{"name":"IGBMC Institute of Genetics, Molecular and Cellular Biology, CNRS, UMR7104 INSERM U964, Strasbourg University, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3322\/caac.21321","article-title":"Cancer statistics: Breast cancer in situ","volume":"65","author":"Ward","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djp482","article-title":"Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes","volume":"102","author":"Virnig","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1002\/mgg3.493","article-title":"BRCA1\/BRCA2 mutations in Japanese women with ductal carcinoma in situ","volume":"7","author":"Liu","year":"2019","journal-title":"Mol. Genet Genom. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.2005.04.0345","article-title":"Ductal carcinoma in situ in BRCA mutation carriers","volume":"25","author":"Hwang","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"WHO (2019). WHO Classification of Tumours: Breast Tumours, WHO. [5th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","article-title":"The natural history of ductal carcinoma in situ of the breast: A review","volume":"97","author":"Erbas","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.7326\/0003-4819-127-11-199712010-00014","article-title":"Using autopsy series to estimate the disease \u201creservoir\u201d for ductal carcinoma in situ of the breast: How much more breast cancer can we find?","volume":"127","author":"Welch","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-013-2598-7","article-title":"Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status","volume":"139","author":"Rauch","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejrad.2004.11.019","article-title":"Mammography of ductal carcinoma in situ of the breast: Review of 909 cases with radiographic-pathologic correlations","volume":"54","author":"Barreau","year":"2005","journal-title":"Eur. J. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jmri.26985","article-title":"Role of Breast MRI in the Evaluation and Detection of DCIS: Opportunities and Challenges","volume":"52","author":"Greenwood","year":"2020","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejrad.2006.06.010","article-title":"Paget\u2019s disease of the breast: Clinical, mammographic, sonographic and pathologic findings in 52 cases","volume":"60","author":"Oktay","year":"2006","journal-title":"Eur. J. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41379-020-00665-x","article-title":"Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy","volume":"34","author":"Schnitt","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses\u2019 Health Study","volume":"103","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/modpathol.2014.141","article-title":"Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up","volume":"28","author":"Sanders","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_16","first-page":"223","article-title":"Long-term follow-up of in situ carcinoma of the breast","volume":"11","author":"Eusebi","year":"1994","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z","article-title":"The clinical significance of pre-invasive breast carcinoma","volume":"46","author":"Rosen","year":"1980","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/ejbh.galenos.2022.2022-4-3","article-title":"The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future","volume":"18","author":"Mathelin","year":"2022","journal-title":"Eur. J. Breast Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-019-0777-3","article-title":"Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions","volume":"21","author":"Solin","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"2010","author":"Collaborative","year":"2010","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2011.03.045","article-title":"Ductal carcinoma in situ\u2013the influence of the radiotherapy boost on local control","volume":"82","author":"Wong","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101456","DOI":"10.1016\/j.tranon.2022.101456","article-title":"Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review","volume":"22","author":"Schmitt","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clbc.2012.04.006","article-title":"Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ","volume":"12","author":"Shah","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semradonc.2022.01.005","article-title":"Risk Assessment in the Molecular Era","volume":"32","author":"Knowlton","year":"2022","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jmoldx.2021.07.026","article-title":"Molecular Testing in Breast Cancer: Current Status and Future Directions","volume":"23","author":"Sun","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.surg.2019.04.044","article-title":"Evaluating patterns of utilization of gene signature panels and impact on treatment patterns in patients with ductal carcinoma in situ of the breast","volume":"166","author":"Bhutiani","year":"2019","journal-title":"Surgery"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4693-2","article-title":"Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: A combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies","volume":"169","author":"Rakovitch","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","first-page":"96","article-title":"Ductal carcinoma in situ (DCIS)\u2014Precision medicine for de-escalation","volume":"13","author":"Rakovitch","year":"2021","journal-title":"Curr. Breast Cancer Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_33","unstructured":"Team, R.C. (2022). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses inRwith themetaforPackage","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Warnberg, F., Karlsson, P., Holmberg, E., Sandelin, K., Whitworth, P.W., Savala, J., Barry, T., Leesman, G., Linke, S.P., and Shivers, S.C. (2021). Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS). Cancers, 13.","DOI":"10.2139\/ssrn.3869642"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"djw256","DOI":"10.1093\/jnci\/djw256","article-title":"Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ","volume":"109","author":"Rakovitch","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study","volume":"33","author":"Solin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-2-28","article-title":"Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: A meta-analysis of randomized trials","volume":"2","author":"Viani","year":"2007","journal-title":"Radiat. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/tbj.12889","article-title":"Adjuvant radiotherapy versus observation following lumpectomy in ductal carcinoma in-situ: A meta-analysis of randomized controlled trials","volume":"24","author":"Garg","year":"2018","journal-title":"Breast J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.6004\/jnccn.2019.7323","article-title":"Mortality After Invasive Second Breast Cancers Following Prior Radiotherapy for DCIS","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Schmitz, R., Wilthagen, E.A., van Duijnhoven, F., van Oirsouw, M., Verschuur, E., Lynch, T., Punglia, R.S., Hwang, E.S., Wesseling, J., and Schmidt, M.K. (2022). Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14133259"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V","article-title":"A prognostic index for ductal carcinoma in situ of the breast","volume":"77","author":"Silverstein","year":"1996","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","article-title":"Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ","volume":"28","author":"Rudloff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2015.65.1869","article-title":"Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study","volume":"34","author":"Sagara","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/jnci\/djaa179","article-title":"21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma In Situ","volume":"113","author":"Rakovitch","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1245\/s10434-019-07537-y","article-title":"Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score","volume":"26","author":"Zabor","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100607","DOI":"10.1016\/j.adro.2020.10.020","article-title":"A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients with Ductal Carcinoma in Situ of the Breast after Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay","volume":"6","author":"Lei","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jso.23933","article-title":"The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score result","volume":"111","author":"Alvarado","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","article-title":"The Clinical Utility of DCISionRT((R)) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery","volume":"28","author":"Shah","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1200\/JCO.2016.67.8532","article-title":"Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ","volume":"34","author":"Raldow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clbc.2020.10.007","article-title":"Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment","volume":"21","author":"Kim","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer Outcomes in DCIS Patients Without Locoregional Treatment","volume":"111","author":"Ryser","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ\u2014The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: A phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"ref_59","unstructured":"(2022, November 28). Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ClinicalTrials.gov), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03878342."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"TPS603","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","article-title":"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)","volume":"37","author":"Kanbayashi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41588-022-01082-3","article-title":"Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer","volume":"54","author":"Lips","year":"2022","journal-title":"Nat. Genet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/2036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:47:30Z","timestamp":1760122050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12052036"],"URL":"https:\/\/doi.org\/10.3390\/jcm12052036","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}